Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 889 Cr.
- Current Price ₹ 113
- High / Low ₹ 123 / 98.2
- Stock P/E 96.4
- Book Value ₹ 4.01
- Dividend Yield 0.00 %
- ROCE 57.7 %
- ROE 50.2 %
- Face Value ₹ 2.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 41.6%
- Debtor days have improved from 226 to 133 days.
Cons
- Stock is trading at 28.1 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | 4.77 | 35.17 | |
| 0.01 | 3.20 | 19.73 | |
| Operating Profit | -0.01 | 1.57 | 15.44 |
| OPM % | 32.91% | 43.90% | |
| 0.00 | 0.70 | 0.11 | |
| Interest | 0.00 | 0.04 | 0.53 |
| Depreciation | 0.00 | 0.28 | 2.93 |
| Profit before tax | -0.01 | 1.95 | 12.09 |
| Tax % | 0.00% | 25.13% | 24.73% |
| -0.01 | 1.45 | 9.11 | |
| EPS in Rs | -0.50 | 72.50 | 1.60 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 637% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 869% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 42% |
| Last Year: | 50% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11.37 | 11.37 |
| Reserves | 0.17 | 10.69 | 14.05 | 20.28 |
| 0.00 | 1.94 | 5.48 | 16.91 | |
| 3.50 | 3.99 | 18.17 | 18.38 | |
| Total Liabilities | 3.87 | 16.82 | 49.07 | 66.94 |
| 2.67 | 9.74 | 28.42 | 27.06 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.00 | 1.51 | 1.51 |
| 1.19 | 7.08 | 19.14 | 38.37 | |
| Total Assets | 3.87 | 16.82 | 49.07 | 66.94 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | -2.11 | ||
| 0.00 | -7.35 | ||
| 0.00 | 10.63 | ||
| Net Cash Flow | 0.00 | 1.17 | |
| Free Cash Flow | 0.00 | -9.46 | |
| CFO/OP | 0% | -100% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 318.32 | 132.84 | |
| Inventory Days | 317.90 | 66.36 | |
| Days Payable | 2,825.81 | 211.78 | |
| Cash Conversion Cycle | -2,189.58 | -12.57 | |
| Working Capital Days | 114.01 | -26.88 | |
| ROCE % | 19.55% | 57.72% |
Insights
In beta| Mar 2026 | |
|---|---|
| Acquired Ownership Stake - Ashwini Medical Centre % |
|
| Acquired Ownership Stake - Harmony Medicare Private Limited % |
|
| Acquired Ownership Stake - Parekhs Hospital Private Limited % |
|
| Acquired Ownership Stake - Patel Multispeciality Hospital and ICU % |
|
| Acquired Ownership Stake - Patel Pharmacy % |
|
| Acquisition Cost - Ashwini Medical Centre INR |
|
| Acquisition Cost - Harmony Medicare Private Limited INR |
|
| Acquisition Cost - Parekhs Hospital Private Limited INR |
|
| Acquisition Cost - Patel Multispeciality Hospital and ICU INR |
|
| Acquisition Cost - Patel Pharmacy INR |
Extracted by Screener AI
Documents
Announcements
-
Intimation About Payment Of Fine Levied Under Regulation 29 Of SEBI (LODR) Regulations 2015
1d - BSE and NSE each levied Rs. 10,000 fine for delayed Board meeting intimation; company paid on 16 Apr 2026.
-
Intimation Of Receipt Of Notice For Non Compliance With Regulation 29(2)/29(3) Of SEBI (LODR) Regulations 2015
16 Apr - BSE and NSE each imposed Rs. 10,000 plus GST fine for delayed board meeting intimation.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
7 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; all shares remain in demat form.
-
Closure of Trading Window
26 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited FY2026 results; board date to be notified.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Mar
Annual reports
No data available.
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.